2024-03-28 13:51:03 ET
More on Boundless Bio, Inc., Renaissance Capital Greenwich Funds - Renaissance IPO ETF, etc.
Read the full article on Seeking Alpha
For further details see:
Bayer-backed Boundless Bio stock down 8% after $100M IPO2024-03-28 13:51:03 ET
Read the full article on Seeking Alpha
For further details see:
Bayer-backed Boundless Bio stock down 8% after $100M IPOMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
Market:
Audentes Therapeutics Inc. Website:
STARMAP ( S tudy T reating A cquired R esistance: M APK A m p lifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel, oral, selective ribonucleotide redu...
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers Third poster presentation to highlight the potential role of ...
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 ...